Vulvar Diseases
12
5
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
17%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Danish Vulva Cancer Recurrence Study
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis
Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)
Effects of Flourish HEC on Localized Provoked Vulvodynia
Vulvar Disease in Nigeria Observational Study
Treatment Prior to Injection and Biopsy of the Vulva
Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis
Botox on Vulvar Vestibulitis